TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02476825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Flixotide Accuhaler 500 micrograms b.i.d.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accuhaler
Description: Flixotide Accuhaler 500 micrograms b.i.d.
Study: NCT03629236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GrafixPL
Description: Debridement, GrafixPL application, dressing application, standard compression therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Debridement, dressing application, standard compression therapy
Study: NCT01098981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ultrasound as an adjunctive therapy to tPA
Description: * tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with active insonation for 120 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care tPA therapy for acute ischemic stroke
Description: * tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with sham (inactive) insonation for 120 minutes
Study: NCT03085979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burch Colposuspension
Description: Anti-incontinent surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans obturator tape
Description: Anti-incontinent surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tension free vaginal tape
Description: Anti-incontinent surgery
Study: NCT00830245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg/day
Study: NCT03882138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
Study: NCT00449670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)
Description: Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)
Description: Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)
Description: Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)
Description: Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
Study: NCT00613444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumaCare LC-122M non-coherent light source
Description: Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
Study: NCT02596243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-188E
Description: 1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
Study: NCT02460705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologically active human fecal material, OpenBiome
Description: Fecal microbiota transplant
Study: NCT01526044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freestyle Navigator
Description: Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Navigator
Description: Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
Study: NCT02530372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UriCap-F
Description: non-invasive urine collection device for women
Study: NCT03738878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: oral valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: oral valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696
Description: oral LCZ696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696
Description: oral LCZ696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bradykinin
Description: Intra-arterial bradykinin at three graded doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bradykinin
Description: Intra-arterial bradykinin at three graded doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Substance P
Description: Intra-arterial substance P at three graded doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Substance P
Description: Intra-arterial substance P at three graded doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP
Description: Intra-arterial BNP at three graded doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP
Description: Intra-arterial BNP at three graded doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: oral sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: oral sitagliptin
Study: NCT03868852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablets
Description: Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal intensity modulation
Description: Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
Study: NCT01873417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 (DMF)
Study: NCT02931942

Intervention type: OTHER
Intervention: blood withdrawn
Description: venous blood sampling

Intervention type: OTHER
Intervention: blood withdrawn
Description: venous blood sampling

Intervention type: OTHER
Intervention: blood withdrawn
Description: venous blood sampling

Intervention type: OTHER
Intervention: blood withdrawn
Description: venous blood sampling

Intervention type: OTHER
Intervention: blood withdrawn
Description: venous blood sampling

Intervention type: OTHER
Intervention: blood withdrawn
Description: venous blood sampling
Study: NCT01971502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1060469
Description: single rising doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: single rising doses
Study: NCT03569046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: ear block by 0.25% bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: ear block by Normal Saline Flush, 0.9% Injectable Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: general anesthetic
Description: general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthetic
Description: general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypotensives
Description: hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotensives
Description: hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
Study: NCT01129050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Oil
Description: Flaxseed oil capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Oil
Description: Flaxseed oil capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soybean oil capsule
Study: NCT01168973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Ramucirumab)
Description: Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Study: NCT01410682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0,12% digluconate chlorhexidine
Description: Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: toothbrushing
Description: Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
Study: NCT02767323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: excitatory 5Hz rTMS will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: excitatory 5Hz rTMS will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: excitatory 5Hz rTMS will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
Study: NCT01865526

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Six point diet
Description: The 6-point diet is a list of six items indicating how to modify their dietary habits:~1. Do not add salt at table and for cooking;~2. Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~3. Replace noodle or bread with special no-protein food;~4. The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~5. 4-5 servings/day of fruits or vegetables are suggested;~6. Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low protein diet
Description: Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
Study: NCT01473342

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mila Blooms
Description: Behavioral intervention will be administered to 30 adolescent childhood cancer survivors \& their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting \& participation. During the 9th week (Week 17), participants complete one final survey \& accelerometer wear.
Study: NCT06021899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified constraint induced movement therapy
Description: Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy
Description: Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
Study: NCT02809014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice F-Complex
Description: Use of few of dentifrice on brushing for one week, twice day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice F-Complex
Description: Use of few of dentifrice on brushing for one week, twice day.
Study: NCT02779946

Intervention type: DEVICE
Intervention: Fibro Scan

Intervention type: DEVICE
Intervention: Fibro Scan

Intervention type: GENETIC
Intervention: PNPLA3

Intervention type: GENETIC
Intervention: PNPLA3
Study: NCT02809014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice F-Complex + NaF
Description: Use of few of dentifrice on brushing for one week, twice day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice F-Complex + NaF
Description: Use of few of dentifrice on brushing for one week, twice day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice with tara gum
Description: Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice with tara gum
Description: Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
Study: NCT02146742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT01821833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
Study: NCT00415506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
Study: NCT01667536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 99mTc-MIP-1404
Description: A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
Study: NCT03156348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Care
Description: During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations.
Study: NCT04296279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP014
Description: Falciparum Malaria Protein-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP014
Description: Falciparum Malaria Protein-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP014
Description: Falciparum Malaria Protein-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP014
Description: Falciparum Malaria Protein-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP014
Description: Falciparum Malaria Protein-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
Study: NCT04026347

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vesair Balloon
Description: Indwelling, intravesical balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vesair Balloon
Description: Indwelling, intravesical balloon

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham balloon placement
Description: Sham balloon placement procedure